You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 16, 2025

Claims for Patent: 11,596,614

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 11,596,614

Title:	Treatment of intrahepatic cholestatic diseases
Abstract:	Treatment of intrahepatic cholestatic diseases by therapy with seladelpar or a salt thereof.
Inventor(s):	Pol Boudes, Charles A. McWherter
Assignee:	CymaBay Therapeutics Inc
Application Number:	US17/221,784
Patent Claims:	1. A method of treating an intrahepatic cholestatic disease by administering seladelpar or a salt thereof, where the daily dose of seladelpar or a salt thereof is 5 mg, when the dose is calculated as seladelpar. 2. The method of claim 1 where the seladelpar or a salt thereof is seladelpar L-lysine dihydrate salt. 3. The method of claim 1 where the seladelpar or a salt thereof is administered orally. 4. The method of claim 2 where the seladelpar L-lysine dihydrate salt is administered orally. 5. The method of claim 1 where the seladelpar or a salt thereof is administered once/day. 6. The method of claim 2 where the seladelpar L-lysine dihydrate salt is administered once/day. 7. The method of claim 3 where the seladelpar or a salt thereof is administered once/day. 8. The method of claim 4 where the seladelpar L-lysine dihydrate salt is administered once/day. 9. A method of treating an intrahepatic cholestatic disease by administering seladelpar or a salt thereof, where the daily dose of seladelpar or a salt thereof is 10 mg, when the dose is calculated as seladelpar. 10. The method of claim 9 where the seladelpar or a salt thereof is seladelpar L-lysine dihydrate salt. 11. The method of claim 9 where the seladelpar or a salt thereof is administered orally. 12. The method of claim 10 where the seladelpar L-lysine dihydrate salt is administered orally. 13. The method of claim 9 where the seladelpar or a salt thereof is administered once/day. 14. The method of claim 10 where the seladelpar L-lysine dihydrate salt is administered once/day. 15. The method of claim 11 where the seladelpar or a salt thereof is administered once/day. 16. The method of claim 12 where the seladelpar L-lysine dihydrate salt is administered once/day.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.